J9325 Talimogene Laherparepvec - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Talimogene Laherparepvec

Brand Name:

Imlygic

Strength:

1 million plaque forming unites (PFU)

HCPCS:

J9325

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Therapeutic Cancer Vaccine

Minor Drug Class:

Oncolytic Virus

Oral (Y/N):

No

FDA Approval Year:

2015

FDA Discontinuation Year:

CMS Effective Date:

Jan. 1, 2017

CMS Discontinuation Date:

Status:

In Use